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Purpose: Evaluation of the efficacy and side effects profile of Clobazam in a 24-week open-labelled trial involving 26 cases of
drug naı¨ve adult patients with epilepsy.
Methods: The study was an open labelled unicentre trial in which only drug naı¨ve cases with epilepsy were included. A total of
26 cases were recruited. One case was dropped because he did not complete the desired follow up. Seizure type and frequency
were recorded and follow up was done at 4, 8, 12, 18 and 24 weeks after initiation of therapy. The change in seizure severity,
the dose of Clobazam required and development of side effects were recorded.
Results: The seizure types included GTCS (n = 16), complex partial seizures (n = 4), focal motor seizures with secondary
generalisation (n = 3) and juvenile myoclonic epilepsy (n = 2). Out of 25 patients, 16 (64%) became seizure free, while five
(20%) had >50% reduction in their seizure frequency. Thus, these 21 patients (84%) were considered to be well controlled.
The commonest side effect seen was sedation, which was noted in 4 of the 25 patients (16%). However, in none of these four
patients sedation was significant enough to warrant stoppage of therapy. Weight gain, gait ataxia, loss of short-term memory and
breakthrough seizures were noted in one patient each.
Conclusions: The efficacy of Clobazam coupled with the lack of significant side effects noted in our study makes it merit
consideration as monotherapy in adult patients with epilepsy.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Epilepsy is considered to be the most common neuro-
logical condition in developing countries. In as many
as 70–80% of epileptic patients, seizures can be
controlled with the commonly prescribed antiepi-
leptic drugs (Phenytoin, Phenobarbitone, Valproate
and Carbamazepine). However, 20–30% of the pa-
tients continue to have seizures despite optimal
therapy1, 2. Further, many patients receiving the stan-
dard anti-epileptic drugs (AEDs) may develop un-
acceptable side effects. Thus, there is a need for
another antiepileptic drug, especially one that can
be prescribed as monotherapy. Clobazam is one of
the promising antiepileptic drugs that has proved its
efficacy as an add on drug in refractory partial and
generalised seizures3. In view of the encouraging re-
sults with Clobazam as add on therapy in refractory
epilepsy, The Canadian Clobazam Co-operative Group
suggested that a monotherapy trial with Clobazam
in less severe epilepsy is now desirable3. Though,
recently the Canadian Study Group for Childhood
Epilepsy suggested the usefulness of Clobazam as
monotherapy in the paediatric age group4, but to the
best of our knowledge there is no published report
on Clobazam Monotherapy in adult patients with
epilepsy.
Clobazam is a 1,5-benzodiazepine, which differs
from conventional 1,4-benzodiazepines (e.g. di-
azepam) in having 80% lesser anxiolytic activity, ten
fold lesser sedative effects and no addictive potential5.
Its antiepileptic effects are due to its action on the
GABA (gamma amino butyric acid) receptor complex
and also on voltage sensitive calcium ion conductance
and sodium channels. Following single oral dose,
peak serum concentration is reached in 2 hours6.
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It is converted to its active metabolite (des-methyl
Clobazam/nor-Clobazam) by hepatic oxidation7.
Clobazam has minimal drug interactions except for
a slight but significant reduction in the clearance of
Valproic acid and Primidone. Adverse effect profile
is generally mild and the discontinuation rate is much
lower than that of the conventional AEDs. Side effects
include sedation, dizziness, ataxia, blurred vision and
diplopia. Though sedation is the most common side
effect, the tendency to develop tolerance is considered
to be the most problematic side effect8. Trials are re-
quired to define the role of Clobazam as monotherapy
in epilepsy, covering all age groups. We report the
results of the efficacy of Clobazam as monotherapy in
adult patients with epilepsy in an open labelled study.
MATERIAL AND METHODS
A pilot open labelled study was formulated to study
the efficacy and safety of Clobazam as first line
monotherapy in the treatment of newly diagnosed
drug naı¨ve patients with epilepsy. The ethical clear-
ance from the institution ethical committee was
obtained before starting the trial.
The purpose of the clinical study and the nature of
drug treatment were explained to all the patients and
a written informed consent was obtained. An option
was given to the patients to opt out of the study at any
time. A total of 26 cases (above the age of 12 years)
were recruited. One patient was dropped, as he did not
follow up after 12 weeks of therapy. The mean age
was 20.84 years (range = 13–36 years) and the pa-
tients included 14 males and 11 females (male/female
ratio = 1.27:1). The change in seizure severity, the
dose of Clobazam required and development of side
effects were recorded at 4, 8, 12, 18 and 24 weeks
after initiation of therapy as per the defined protocol.
The patients were instructed to report immediately if
they had recurrence of seizures or developed adverse
events.
The inclusion criteria were as follows:
1. Newly diagnosed untreated patients with epilepsy
having a seizure frequency of at least two seizures
per 4 weeks in the last 12 weeks.
2. Patients of both sexes aged 12 years and above.
The exclusion criteria were as follows:
1. Pregnant women or those planning a pregnancy
in the next 6 months.
2. Patient with severe liver, renal, cardiac, gastroin-
testinal or progressive neurological disease.
3. Past history of psychosis or behavioural prob-
lems.
4. History of drug/alcohol abuse or addiction.
5. Inability to keep a good seizure calendar and at-
tend the epilepsy clinic at regular intervals for
follow up evaluation.
Routine investigations (haematology, liver function
and renal function tests) were done to rule out any co-
existing disease. Cranial CT scan was done in all pa-
tients. Clobazam (Frisium, Aventis Pharma Ltd.) was
started at an initial dose of 10 mg and increased to
20 mg after a week. In subjects whose seizures were
not controlled with 20 mg, further increments of 10 mg
per week were added till seizure control was attained.
At the end of follow up of minimum of 24 weeks,
patient’s seizure control was classified as:
• Excellent If patient was seizure free
• Improved If patient had seizures at a
frequency <50% of
baseline
• Minimally improved If patient had seizures at a
frequency >50% of
baseline
• Not controlled If patient had no change
in frequency of seizures




Our study analysed 26 patients, of which one was not
available for follow up. The duration of follow up was
15.64 months (range = 7–24 months). Average dose
of Clobazam used was 26.86 mg (range 20–80 mg).
The seizure types included GTCS (n = 16), com-
plex partial seizures (n = 4), focal motor seizures
with secondary generalisation (n = 3) and juvenile
myoclonic epilepsy (n = 2).
Of the 25 patients, 16 (64%) became seizure free,
while five (20%) had >50% reduction in their seizure
frequency. Thus, these 21 patients (84%) were con-
sidered to be well controlled. Considering the seizure
subtypes, 14 out of 16 patients with GTCS were well
controlled, two out of four (50%) with CPS were well
controlled, all three patients with focal seizures and
both the patients with juvenile myoclonic epilepsy
were well controlled.
Sixteen out of 20 (80%) patients with a normal
CT scan were well controlled, while all five patients
(100%) with abnormality on CT scan also responded
well to Clobazam monotherapy. All the patients with
CT abnormality had single ring enhancing lesions. Fo-
cal seizures were the presenting feature in three of
these patients, while two patients had GTCS.
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Of these 21 patients whose seizures were considered
well controlled, 16 (76%) were controlled by the 4th
week, four were controlled by the 8th week and one
was controlled by the 12th week.
The commonest side effect seen was sedation,
which was noted in 4 of the 25 patients (16%). Weight
gain, gait ataxia and loss of short-term memory were
noted in one patient each. Breakthrough seizures
were seen in one patient with GTCS. This patient
was taking a dose of Clobazam 40 mg per day. The
dose was increased to 80 mg in the next 4 weeks but
the seizures were not well controlled. Carbamazepine
was added and seizures were well controlled on a
dose of 25 mg/kg body weight per day and Clobazam
was slowly tapered. None of the other side effects
warranted discontinuation of therapy.
DISCUSSION
In our study, no correlation was noted between ef-
ficacy and side effects of Clobazam with either age
or sex of the patient. Of the 25 patients who com-
pleted the study, 16 (64%) were seizure free, while
five (20%) had greater than 50% reduction in seizure
frequency. This figure compares well with the Cana-
dian Study Group for Childhood Epilepsy4 and also
with other studies using Lamotrigine9 or Topiramate10
as monotherapy in which the seizure free percentage
of patients varied from 45 to 65%. To the best of our
knowledge there is no other trial using Clobazam as
monotherapy in adults with epilepsy, hence no com-
parison is possible.
The drop out rate in our study was a 1 out of 26
patients in the mandatory first 6-months study period.
Another one out of the remaining 25 patients who
developed an increase in seizure frequency (break-
through seizures) in the fourth month had to be
changed to another drug but was available for follow
up till 24 weeks of the study period. Thus 96.0% pa-
tients completed the study, which compares very well
with other trials using Lamotrigine and Topiramate.
Among 21 patients who had good seizure control, 16
(76.0%) patients were controlled by the 4th week of
therapy; four by the 8th week and one was controlled
by the 12th week. It was noted that if seizures were not
controlled by the third month of treatment then they
were unlikely to respond to Clobazam monotherapy.
Sedation was the commonest side effect noted, but
it was not disabling. Weight gain, gait ataxia, loss of
short-term memory and break through seizures were
other adverse effects noted. The side effect profile
noted in our series is in concordance with other stud-
ies, which used Clobazam as add on therapy. Signifi-
cantly, however, we did not find tolerance to be a major
side effect in our series. The Canadian Study Group
for childhood epilepsy found tolerance to be a prob-
lem in 7.5% of their patients. Small sample size was
the main drawback of our study. Unlike other studies
the efficacy of Clobazam as a monotherapy in com-
parison to standard antiepileptics was not undertaken
in the present study.
The efficacy of Clobazam coupled with its lack of
significant side effects, as seen in our patient series,
makes it a potentially useful drug in the physician’s ar-
mamentarium in the battle against epilepsy. Also this
drug is not very expensive compared to the other newer
antiepileptic drugs available. In India, per day cost of
therapy with Clobazam is one third of topiramate, half
of lamotrigine and approximately the same as that of
Valproate and Carbamazepine therapy. This pilot study
may thus be considered as a starting point for for-
mulating further trials using Clobazam as monother-
apy so as to define its role further in the management
of epilepsy. A multicentre trial comparing Clobazam
with other antiepileptic drugs like Carbamazepine or
Phenytoin needs to be planned.
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